Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of AP-472 conducted in healthy young, middle-aged, and elderly adults

Next Previous
X
Search
Trial Profile

A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of AP-472 conducted in healthy young, middle-aged, and elderly adults

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AP-472 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions

    • Most Recent Events

    • 26 Oct 2021 New trial record
    • 04 Oct 2021 According to an Appello Pharmaceuticals media release, first patient has been enrolled in this study. The study is enrolling subjects at Worldwide Clinical Trials in San Antonio, Texas. Findings from this study will be use for the dose selection of Phase 1b and Phase 2 clinical studies in people with Parkinson's disease.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top